Amarin Corp Plcuk (AMRN) Non-Current Deffered Revenue (2015 - 2024)
Amarin Corp Plcuk (AMRN) posted quarterly Non-Current Deffered Revenue of $2.1 million for Q1 2024, down 83.4% YoY from $12.7 million in Q2 2023, and down 15.98% sequentially from $2.5 million in Q4 2023.
Amarin Corp Plcuk (AMRN) Non-Current Deffered Revenue (2015 - 2024) Analysis & Trends
Amarin Corp Plcuk has disclosed Non-Current Deffered Revenue across 10 years of filings, most recently posting $2.1 million for Q1 2024.
- In Q1 2024, Non-Current Deffered Revenue fell 83.4% year-over-year to $2.1 million; the TTM figure through Mar 2024 stood at $2.1 million (down 83.4% YoY), while the FY2023 annual figure was $2.5 million, down 80.92% from the prior year.
- Non-Current Deffered Revenue eased to $2.1 million in Q1 2024, from $2.5 million in the prior quarter.
- Over the last five years, Non-Current Deffered Revenue for AMRN reached as high as $17.5 million in Q1 2020 and fell as low as $2.1 million in Q1 2024.
- The 5-year median for Non-Current Deffered Revenue is $13.8 million (2022), against an average of $11.6 million.
- Annual changes were most pronounced in 2021 — Non-Current Deffered Revenue rose 9.75% — and 2024, when it slumped 83.4%.
- A 5-year view of Non-Current Deffered Revenue shows it stood at $15.7 million in 2020, then dropped by 10.48% to $14.1 million in 2021, then declined by 6.49% to $13.1 million in 2022, then tumbled by 80.92% to $2.5 million in 2023, then declined by 15.98% to $2.1 million in 2024.
- According to Business Quant data, Non-Current Deffered Revenue over the past three periods registered $2.1 million, $2.5 million, and $2.9 million for Q1 2024, Q4 2023, and Q3 2023 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Deffered Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | - |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | - |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | - |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | - |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | - |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | - |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | - |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | - |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Amarin Corp Plcuk | 5.17 Bn | 5.00 Bn | 17.77 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2024 | 2.11 Mn |
| Dec 31, 2023 | 2.51 Mn |
| Sep 30, 2023 | 2.95 Mn |
| Jun 30, 2023 | 3.33 Mn |
| Mar 31, 2023 | 12.70 Mn |
| Dec 31, 2022 | 13.15 Mn |
| Sep 30, 2022 | 13.50 Mn |
| Jun 30, 2022 | 13.81 Mn |
| Mar 31, 2022 | 14.14 Mn |
| Dec 31, 2021 | 14.06 Mn |
| Sep 30, 2021 | 14.49 Mn |
| Jun 30, 2021 | 14.83 Mn |
| Mar 31, 2021 | 15.20 Mn |
| Dec 31, 2020 | 15.71 Mn |
| Sep 30, 2020 | 13.20 Mn |
| Jun 30, 2020 | 14.51 Mn |
| Mar 31, 2020 | 17.52 Mn |
| Dec 31, 2019 | 18.50 Mn |
| Sep 30, 2019 | 17.62 Mn |
| Jun 30, 2019 | 17.78 Mn |